secwatch.observer — SEC 8-K summary
======================================

Issuer:     CITIUS ONCOLOGY, INC. (CTOR)
CIK:        0001851484
Form:       8-K
Filed at:   2026-05-15T20:44:23+00:00
Accession:  0001213900-26-057883
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Citius Oncology reports Q2 FY2026 net loss $26.6M; LYMPHIR revenue $1.7M, launch progressing
--------------------------------------------------------------------------------

- Net product revenues $1.7M in Q2 ($5.6M H1) vs $0 prior year; gross margin 80%.
- Net loss $26.6M vs $7.7M prior year, driven by $19.7M one-time CMO contract cancellation.
- Cash $2.6M at March 31; subsequent $11.5M warrant exercise and $10M debt tranche from Avenue Capital ($25M facility).
- 83% of target accounts on formulary or in review; near 100% payer coverage; initial European shipment.
- Hired Jefferies as exclusive financial advisor to evaluate strategic alternatives; combined cash runway through Nov 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1851484/000121390026057883/0001213900-26-057883-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1851484/000121390026057883/ea0291035-8k_citius.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-057883

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer